Company intelligence / Profile preview

Jina Pharmaceuticals, Inc.

Libertyville, Illinois, USAjinapharma.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Jina Pharmaceuticals develops innovative therapies using advanced drug delivery platforms. Its lead asset, Endoxifen, has reached Phase III trials for bipolar disorder in the US as of March 2024. The company also has programs in breast cancer and organ transplantation with a focus on improving treatment efficacy and reducing side effects through proprietary formulation technologies. Some products have achieved approval outside the US.

Therapeutic areas: OncologyImmunologyPsychiatryDermatology
Modalities: Small moleculesLipid-based formulations (e.g., Nanoaqualip platform)
Industry: Biotech

Partnerships

Intas Pharmaceuticals (co-developer of Endoxifen)National Cancer Institute USA involved as developer/collaborator for Endoxifen clinical studies.

Beyond the preview

Go deeper on Jina Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jina Pharmaceuticals, Inc..

Explore the full profile